Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
https://www.embs.org/ojemb/wp-content/uploads/sites/20/2020/02/ojemb-gagraphic-2962801-1.jpg
742
558
IEEE Open Journal of Engineering in Medicine and Biology (OJEMB)
//www.embs.org/ojemb/wp-content/uploads/sites/20/2022/06/ieee-ojemb-logo2x.png
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, accounting for 50% of all cases. GBM patients have a five-year survival rate of merely 5.6% and a median…
read more